346-360 of 931
Cardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks
Project Oncology®Cardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks
Parul Rai
Balancing Benefits and Risks in Emerging Sickle Cell Therapies
Project Oncology®Balancing Benefits and Risks in Emerging Sickle Cell Therapies
Yogindra Persuad
The Transition from Pediatric to Adult Care for Patients with Sickle Cell Disease
Project Oncology®The Transition from Pediatric to Adult Care for Patients with Sickle Cell Disease
Nidhi Bhatt
Sickle Cell Disease Care: Examining Hydroxyurea and Chronic Transfusions
Project Oncology®Sickle Cell Disease Care: Examining Hydroxyurea and Chronic Transfusions
Parul Rai
Building a Multidisciplinary Care Team for Sickle Cell Disease Patients
Project Oncology®Building a Multidisciplinary Care Team for Sickle Cell Disease Patients
Nidhi Bhatt
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
- advertisement
Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Clinician's RoundtableConsensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Targeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Clinician's RoundtableTargeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Project Oncology®Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Charles Turck, PharmD, BCPS, BCCCP
Matthew Lunning, DO, FACP
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Project Oncology®Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Aline Fares, MD
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Project Oncology®Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Ryan Quigley
David F. McDermott, MD
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Project Oncology®Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Jorge Nieva, MD
- advertisement
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Project Oncology®One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
On the Frontlines of Prostate CancerNew Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
Wayne Kuang, MD
William Oh, MD
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
On the Frontlines of Prostate CancerWhy Words Matter: Rethinking Terminology in Advanced Prostate Cancer
William Oh, MD